NCT02890069 2023-01-11A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatNovartisPhase 1 Completed298 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT02466568 2019-09-09Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the LungH. Lee Moffitt Cancer Center and Research InstitutePhase 1/2 Withdrawn